A study to compare two pediatric formulations to the adult formulation of cobicistat 150 mg tablet in healthy adult volunteers To evaluate the relative bioavailability of two age-appropriate pediatric formulations (immediate release tablet or dispersible tablet as suspension) of COBI in healthy adult subjects

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A trial investigating the safety and efficacy of a drug combination Ledipasvir/Sofosbuvir for Subjects with hepatitis C who are on dialysis for kidney disease  To evaluate the antiviral efficacy of treatment with LDV/SOF for 8,12, or 24 weeks in subjects with chronic hepatitis C virus (HCV) infection who are on dialysis for ESRD, as measured by the proport...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A trial investigating the safety and efficacy of a drug combination Sofosbuvir/Velpatasvir for Adolescents and Children with hepatitis C PK Lead-in phase is: To evaluate the steady state pharmacokinetics (PK) and confirm the dose of sofosbuvir/velpatasvir (SOF/VEL) in pediatric subjects with chronic hepatitis C virus (HCV) infection ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase 3, Double-Blind Extension Study of Idelalisib (GS-1101) at Different Dose Levels for Previously Treated CLL patients (a Companion Trial to GS-US-312-0116) • To evaluate the effect idelalisib (formerly GS-1101) on the onset, magnitude, and duration of tumor control • To compare tumor control in subjects receiving rituximab alone in Study GS-US-312-0116...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Bioavailabity and food effects of the paediatric formulation of LDV/SOF in adult subjects To evaluate the relative bioavailability of a pediatric granules formulation of ledipasvir/sofosbuvir (LDV/SOF) relative to tablet formulation in healthy subjects. To evaluate the effect of conco...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study to test the safety, tolerability and ability to maintain HIV suppression of of switching from a current regimen consisting of abacavir/lamivudine (ABC/3TC) plus a third antiretroviral agent to the elvitegravir/cobicistat/emtricitabine/tenofovir Alafenamide (E/C/F/TAF) fixed-dose combination (FDC) in the HIV-1 infected subjects who are virologically suppressed. Estudio para evaluar la seguridad, tolerabilidad y la capacidad de mantener la supresión de VIH al pasar de un régimen de abacavir / lamivudina (ABC/ 3TC) más un tercer agente antirretroviral a una combinación de dosis fija (FDC) de elvitegravir / cobicistat / emtricitabina / tenofovir alafenamida (E / C / F / TAF) ) en sujetos adultos infectados por el VIH-1 con supresión virológica To evaluate the efficacy of switching to E/C/F/TAF FDC relative to continuing on a baseline regimen consisting of ABC/3TC plus a third antiretroviral agent in maintaining HIV-1 RNA < 50 copies/mL at W...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension A Phase 3 Randomized, Double-Blind, Placebo- and Active-Controlled, Multi-center, Parallel Group Study to Evaluate the Safety and Efficacy of Darusentan in Subjects with Resistant Hypertension Receiving Combination Therapy with Three or More Antihypertensive Drugs, Including a Diuretic, as Compared to Guanfacine or Placebo The primary objective of this study is to determine if darusentan is effective in reducing SBP and DBP in subjects who have RHTN, despite being treated with full doses of three or more antihypertensiv...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study to see if HIV-1 positive subjects currently taking an anti-retroviral (ARV) regimen consisting of Truvada®, can safely switch to F/TAF without increasing the amount of HIV-1 in their blood To evaluate the efficacy of switching FTC/TDF to F/TAF versus maintaining FTC/TDF in HIV-1 positive subjects who are virologically suppressed on regimens containing FTC/TDF as determined by the propor...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study to evaluate how different combinations of antiviral agents, when given with standard medicines, affect the treatment outcome of patients infected with the Hepatitis C Virus (HCV) To evaluate the antiviral efficacy as measured by sustained virologic response (SVR, defined as plasma HCV RNA < LLoQ at 24 weeks post-treatment) of response guided therapy (RGT) with GS-5885 + GS-945...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

This study will test an experimental drug called GS-9883/emtricitabine/tenofovir alafenamide (GS-9883/F/TAF) fixed dose combination (FDC) for the treatment of HIV-1 infection. The purpose of this study is to test safety and to test whether GS-9883/F/TAF as a FDC works as well as the FDC drug containing abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) (trade name Triumeq). The study will also test whether GS-9883/F/TAF maintains the control of HIV-1 infection effectively compared to ABC/DTG/3TC To evaluate the efficacy of a fixed dose combination (FDC) containing GS-9883/emtricitabine/tenofovir alafenamide (GS-9883/F/TAF) versus a FDC containing abacavir/dolutegravir/lamivudine (ABC/DTG/3TC)...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune